![]() |
|
|
Vol. 61, Issue 2, 285-293, February 2002
Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, Nevada
| |
Abstract |
|---|
|
|
|---|
The regulation of cardiac delayed rectifier potassium (Kv) currents by
cAMP-dependent protein kinase (PKA) contributes to the control of blood
pressure and heart rate. We investigated the modulation by PKA and
protein phosphatases of cloned Kv1.5 channels expressed in
Xenopus laevis oocytes. Exposure of oocytes to
activators of PKA (100 nM forskolin, 1 mM 8-bromo-cAMP, or 1 mM
3-isobutyl-1-methylxanthine) had no effect on the amplitude of Kv1.5
currents. Inhibition of PKA by injection of protein kinase A inhibitor
peptide or exposure to myristoylated protein kinase A inhibitor peptide
(M-PKI; 100 nM) reduced currents mediated by Kv1.5. M-PKI also reduced
the amplitude of currents mediated by mutated Kv1.5 channels in which
the COOH terminal PKA phosphorylation sites and PSD-95, Disc-large, and
ZO-1-binding domain were removed. The reduction of Kv1.5 currents by
M-PKI was attenuated by inhibition of actin polymerization by 1 µM
cytochalasins B and D, but was not affected by 10 µM phalloidin
(stabilizes actin filaments) or 50 µM colchicine (disrupts
microtubules). Treatment of oocytes with antisense oligonucleotides
against
-actinin-2 abolished the reduction in Kv1.5 current by
M-PKI. These observations suggest that Kv1.5 currents are activated by
endogenous PKA in "resting" oocytes and that inhibition of PKA
activity reveals the action of endogenous phosphatases. Indeed,
injection of alkaline phosphatase reduced currents mediated by Kv1.5.
Further preincubation of oocytes with 1 mM sodium orthovanadate (a
protein tyrosine phosphatase inhibitor) abolished the reduction in
Kv1.5 currents by M-PKI. We conclude that currents encoded by Kv1.5 are
regulated by PKA and protein tyrosine phosphatase and that this
regulation requires an intact actin cytoskeleton and
-actinin-2.
| |
Introduction |
|---|
|
|
|---|
In
cardiac myocytes, delayed rectifier potassium (Kv) currents mediate
IK, important in the repolarization of action
potentials of ventricular and atrial myocytes (Firek and Giles, 1995
).
Different components of IK have been identified
in cardiac myocytes and, in some cases, components of
IK have been attributed to specific Kv channels
(Barry and Nerbonne, 1996
). For example, many cardiac myocytes have
rapidly activating, slowly inactivating components of
IK referred to as IKur
(ultra-rapid). This current is distinguished by its rapid activation
kinetics and relatively high sensitivity to 4-AP (Nattel et al., 1999
).
The kinetic and pharmacological properties of
IKur in human and rat atrial myocytes resemble
those of cloned Kv1.5 channels (Paulmichl et al., 1991
; Fedida et al., 1993
; Overturf et al., 1994
). In support of a role for Kv1.5 currents in atrial myocytes, Kv1.5 was cloned from human and rat atria (Paulmichl et al., 1991
; Fedida et al., 1993
) and mRNA encoding this
channel and Kv1.5 protein have been detected in rat atria (Dixon and
McKinnon, 1994
; Mays et al., 1995
). Furthermore, treatment of cultured
rat and human atrial myocytes with antisense oligonucleotides designed
to reduce expression of Kv1.5 channels attenuated the magnitude of
IKur (Feng et al., 1997
; Bou-Abboud and Nerbonne, 1999
). Thus, a variety of functional and molecular data suggest that
Kv1.5
subunits mediate IKur in human and rat
atrial myocytes.
IKur is characteristically increased by the
activity of PKA as part of the response to
-adrenergic activation
(Li et al., 1996
; Yue et al., 1999
). To elucidate the molecular
mechanisms underlying the increase in IKur after
PKA stimulation, responses of cloned Kv channels to activation and
inhibition of protein kinases have been studied in heterologous
expression systems. However, it has been difficult to relate the
behavior of heterologously expressed channels with that of native
channels.
-Adrenergic activation of PKA increased Kv1.2 currents
expressed in Xenopus laevis oocytes (Huang et al., 1994
) but
acute activation of PKA had no effect on full-length Kv1.1 or Kv2.1
currents (Wilson et al., 1994
; Levin et al., 1995
). Interestingly, the
varied responses to the activation of PKA in X. laevis
oocytes are not limited to Kv channels. For example, activation of PKA
increases heterologously expressed cystic fibrosis transmembrane
conductance regulator currents (Levesque et al., 1992
) but not L-type
Ca2+ currents (Singer-Lahat et al., 1994
).
Taken together, these findings suggest that the ability of a channel to
respond to PKA may depend on the organization of the channels with
respect to the endogenous protein kinases and phosphatases. As
discussed in recent reviews (Johnson, 1999
; Sheng and Pak, 2000
),
colocalization of kinases, phosphatases and their substrates provides
for specificity of control and increases the speed of response. Thus,
one expects that kinases and phosphatases will not be freely mobile,
that they will be located near their substrates, and that this
organization will influence function. However, the relationship between
Kv channels, regulatory proteins, and the cytoskeleton is largely
unknown. Previous work has focused on the PDZ-binding domains of Kv1
family members that localize these channels at synapses (Tejedor et
al., 1997
;Tiffany et al., 2000
) and the binding of Kv1.5 channels to
-actinin-2 (Maruoka et al., 2000
).
-Actinin-2 is a dimer of two
antiparallel peptides each containing two EF-hand domains and an
actin-binding domain separated by a 30-nm spacer of four spectrin
repeat motifs (Beggs et al., 1992
). The actin-binding domains enable
-actinin-2 to bundle actin microfilaments, whereas the spectrin
repeat domain binds to human Kv1.5 (Maruoka et al., 2000
; Cukovic et
al., 2001
) and to NMDA receptors (Wyszynski et al., 1997
). The
combination of channel-binding and actin-binding domains gives
-actinin-2 the ability to link channels to the actin cytoskeleton,
thereby localizing them near regulatory kinases and phosphatases.
In this study, we examined the regulation of Kv1.5 channels by PKA and
protein phosphatases using the X. laevis oocyte expression system. We find that there is a basal activation of Kv1.5 channel currents by endogenous PKA and that the regulation of these channels involves protein tyrosine phosphatase and an intact cytoskeleton. Some
of these results have been presented in abstract form (Mason et al.,
2001
).
| |
Materials and Methods |
|---|
|
|
|---|
Creation of Kv1.5
C59 Mutant.
Kv1.5 cloned from the canine
colon (Overturf et al., 1994
) possesses two potential PKA
phosphorylation sites at Ser538 and
Ser545, and a PDZ-binding domain at the COOH
terminus. We deleted the terminal 59 residues of canine Kv1.5 COOH
terminus to remove these sites (Kv1.5
C59). To confirm the mutation,
the Kv1.5
C59 construct was sequenced using the ABI Prism sequencing
kit (Applied Biosystems, Foster City, CA) and analyzed on a
Genetic Analyzer 310 (ABI). Plasmid DNA was linearized with
NdeI, and capped transcripts were synthesized in vitro with
T7 RNA polymerase with the T7 mMessage mMachine transcription kit
(Ambion, Austin, TX).
-Actinin-2 Antisense Experiments.
The sequence of
-actinin-2 antisense and sense oligonucleotides were as described by
Maruoka et al. (2000)
. Phosphorothioate oligonucleotides were
synthesized by Biosource International (Foster City, CA) and diluted in
molecular biology grade water to 1 µg/µl.
Isolation and Two-Microelectrode Voltage-Clamp of Oocytes.
X. laevis oocytes were isolated as described previously
(Overturf et al., 1994
). Stage V and VI oocytes were injected with 50 nl of cRNA encoding either Kv1.2 (1.9 µg/µl; GenBank accession number L19740), Kv1.5 wild-type (0.035 µg/µl; GenBank accession number U08596), Kv1.5
C59 (3.8 µg/µl), Kv2.2 (1.9 µg/µl;
GenBank accession number U69962), or Kv3.1 (Y07521, 0.06 µg/µl) using a Drummond Nanoject microinjector (Drummond Scientific Co, Broomall, PA). Whole-cell currents were recorded using the
two-microelectrode voltage-clamp technique. Glass microelectrodes were
filled with 3 M K-aspartate and had resistances of 1 to 3 M
. Oocytes
were superfused with a low chloride Ca2+-free
solution designed to minimize the endogenous
Ca2+-activated Cl- current.
This solution contained 96 mM Na isethionate, 2 mM KCl, 2.8 mM
MgCl2, 5 mM HEPES, and 0.05 mM niflumic acid, pH
7.4. Reagents were either applied to the bath (volume, 0.5 ml) via a
gravity-fed perfusion system or injected into the oocyte. The mixing
time to exchange bath solutions was approximately 30 s. Each
experiment was performed at room temperature (24-28°C) on oocytes
collected from two or more frogs. Voltage protocols were applied using
pCLAMP 6.0 software (Axon Instruments, Union City, CA). In short,
400-ms voltage steps were applied from a holding potential of
80 mV to test potentials ranging from
50 to +50 mV in 10 mV increments. Linear leak and capacitance currents were removed using a P/5 protocol.
40 mV, plotting the currents as a function of the
activating potential and fitting to the Boltzmann equation to obtain
the half-activation voltage (VAct) and
slope factor (s). We tested the possibility that the effects of the
drugs tested were caused by internalization of the Kv1.5 channels by
monitoring the capacitance of the oocyte membrane. This was measured as
the area under the current elicited by a voltage step from
80 to
70
mV. None of the treatments had a significant effect on membrane capacitance.
Data and Statistical Analysis. Data were analyzed using pCLAMP 6.0 (Axon Instruments) and Origin software (Microcal, Northampton, MA). Values are expressed as the mean ± S.E.M of n oocytes. Statistical analysis was performed using Prism (GraphPad Software, San Diego, CA). Results were analyzed in two ways: the difference from control with respect to time was analyzed using one-way ANOVA, and the difference between groups of oocytes subjected to different treatments was analyzed using two-way ANOVA. When differences over time or between treatments were found by ANOVA, the Bonferroni post hoc test was used, with p values < 0.05 regarded as significant.
Solutions and Drugs. Forskolin and 8-bromo-cAMP were obtained from Sigma (St. Louis, MO). Calf intestine alkaline phosphatase was obtained from Roche Molecular Diagnostics (Indianapolis, IN). All other compounds were obtained from Calbiochem (La Jolla, CA).
| |
Results |
|---|
|
|
|---|
Activators of Protein Kinase A Do Not Affect Kv1.5 Current.
X. laevis oocytes injected with cRNA encoding wild-type
Kv1.5 displayed outward current during step depolarizations to
potentials positive to
20 mV. These currents had the properties of
Kv1.5, as characterized previously (Overturf et al., 1994
), and were not seen in uninjected oocytes. We examined the effect of agents that
stimulate PKA activity on wild-type Kv1.5 current with the results
summarized in Fig. 1. Superfusion of
oocytes with either forskolin (100 nM, A), 8-bromo-cAMP (1 mM, B) or
the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 100 µM, C) over a 15-min period had no effect on the magnitude of Kv1.5
currents. To ensure that PKA was maximally activated, we also examined
the response of wild-type Kv1.5 current to a PKA cocktail that
activates cystic fibrosis transmembrane conductance regulator currents
expressed in X. laevis oocytes (Levesque et al., 1992
). D
shows that the superfusion of the PKA cocktail consisting of forskolin
(10 µM), 8-bromo-cAMP (1 mM) and IBMX (100 µM) had no effect on
Kv1.5 currents. Thus, agents that increase intracellular cAMP levels
have no effect on Kv1.5 currents in X. laevis oocytes. We
then considered the possibility that Kv1.5 channels were already fully
activated by the endogenous PKA activity in X. laevis
oocytes and examined the effect of inhibiting PKA activity on wild-type
Kv1.5 currents.
|
PKA Inhibitor Peptides Reduce Kv1.5 Current.
Protein kinase A
inhibitor peptide (5-24) (PKI 5-24) is a synthetic peptide that
specifically binds to the catalytic subunit of PKA and reduces PKA
activity (Cheng et al., 1986
). Control Kv1.5 currents were recorded for
10 min before oocytes were injected using a third microelectrode with
50 nl of PKI 5-24 (200 µM, to give a final estimated intraoocyte
concentration of 10 µM) or deionized water, and the currents
monitored for a further 30 min. As shown in Fig.
2A, injection of PKI 5-24 caused a
time-dependent reduction in the magnitude of wild-type Kv1.5 current.
PKI 5-24 reduced peak Kv1.5 current over a 30-min period (to 0.61 ± 0.04 of control 30 min postinjection, p < 0.001, n = 7). In contrast, injections of water did not
suppress Kv1.5 current over a 30-min time course (to 0.93 ± 0.03 of control 30 min after injection, n = 4). The
reduction in wild-type Kv1.5 current in oocytes injected with PKI 5-24 was significantly different from water-injected oocytes from 15 min
after injection onwards (p < 0.01, two-way ANOVA).
|
10
mV (data not shown). Both PKI 5-24 and M-PKI caused a slight
hyperpolarizing shift in the voltage required to half-activate the
current. For M-PKI, VAct was
10.9 ± 0.4 mV in control, which shifted to
15.0 ± 0.7 mV after 10-min wash
(n = 6). M-PKI had no effect on the slope of the
activation curve (11.2 ± 0.4 mV in control versus 11.8 ± 0.6 mV after 10-min wash, n = 6) or
t0.5 (15.3 ± 5.8 ms in control versus
11.3 ms ± 3.5 after 10-min wash, n = 6). The
reduction in the Kv1.5 current was not caused by a shift in the
reversal potential (ERev =
85.7 ± 1.5 mV
control, ERev =
87.3 ± 1.1 mV after 15 min M-PKI, and ERev =
83.4 ± 10.0 mV
after 10-min wash, n = 4). Thus, inhibition of PKA
activity by specific PKA inhibitory peptides caused a significant
reduction in wild-type Kv1.5 conductance.
In the following experiments, we used the membrane-permeant PKA
inhibitor M-PKI to minimize the experimental difficulties encountered
after the insertion of a third microelectrode during recording. We saw
variability in the reduction in Kv1.5 currents in response to M-PKI
from 25% (e.g., Figure 3C) to 60%
(e.g., Figure 2). This is similar to the suggestion by Ivanina et al. (1994)
|
The Effect of PKA Activators and Inhibitory Peptides on Other Kv Channels. To examine whether differences in the primary structure of Kv channels determined their regulation by PKA we examined the effects of forskolin, 8-bromo-cAMP, and M-PKI on other Kv family members (Kv1.2, Kv1.5, Kv2.2, and Kv3.1); results are summarized in Fig. 3. As observed for Kv1.5, superfusion for 15 min with forskolin (100 nM, Fig. 3A) or 8-bromo-cAMP (1 mM, Fig. 3B) had no effect on the magnitude of any of the Kv currents examined. These data imply that like Kv1.5, channels encoded by Kv1.2, Kv2.2, and Kv3.1 do not respond to agents that increase intracellular cAMP levels when expressed in X. laevis oocytes.
We also investigated the sensitivity of these Kv channels to M-PKI. As shown in Fig. 3C, Kv1.2 currents were slowly reduced by M-PKI (100 nM, 0.63 ± 0.08 of control after 15 min 100 nM M-PKI, p < 0.05) that decreased further on washout (to 0.51 ± 0.09, p < 0.01, n = 5). In contrast, Kv2.2 and Kv3.1 currents were unaffected by superfusion of M-PKI. Thus, inhibition of PKA by PKA inhibitor peptides suppressed Kv1.5 and Kv1.2 currents in oocytes, but not Kv2.2 or Kv3.1 currents.Expression and Modulation of Mutant Kv1.5
C59.
We examined
the amino acid sequence of each of the Kv channels for differences that
could account for the variability in the response to M-PKI shown in
Fig. 3. All the Kv channels have potential PKA phosphorylation sites on
the intracellular termini; wild-type Kv1.5 cloned from the canine colon
(Overturf et al., 1994
) possesses only two consensus PKA
phosphorylation sites (R/K-R/K-X-S/T), both on the COOH terminus at
Ser538 and Ser545. A
notable difference between the Kv1 family and the Kv2 and Kv3 families
is the presence of a PDZ sequence at the COOH terminus of Kv1 family
members. This sequence motif mediates the interaction between Kv1.1 and
the cytoskeleton (Jing et al., 1997
). Furthermore, these workers
suggested that PKA regulated the extent of this interaction. We created
a COOH-terminal deletion that removed the terminal 59 amino acid
residues from canine Kv1.5 deleting both the potential PKA
phosphorylation sites and the PDZ-binding domain (E-D-S-V). We injected
oocytes with sufficient cRNA encoding Kv1.5
C59 (100× higher
concentration) to give currents of a similar magnitude as wild-type
Kv1.5 and examined the response to M-PKI (100 nM) with the results
summarized in Fig. 4. Kv1.5
C59
currents were 0.89 ± 0.03 of control after 15 min M-PKI, and
reduced further to 0.76 ± 0.04 of control after 10-min wash at a
test potential of +50 mV (n = 13). This was not
significantly different from wild-type currents (0.90 ± 0.03 of
control after 15 min M-PKI, 0.78 ± 0.04 of control after 10-min
wash, n = 9). Therefore, the modulation of Kv1.5 by PKA
does not require phosphorylation of the PKA phosphorylation sites on
the COOH terminus, nor an interaction between the PDZ domain and the
cytoskeleton.
|
Modulation of Kv1.5 Currents by PKA Requires an Intact
Cytoskeleton.
We investigated further whether the cytoskeleton was
involved in the PKA modulation of wild-type Kv1.5 by preincubating
oocytes for at least 4 h with cytoskeletal modifying agents and
examining the response to M-PKI. The results of these experiments are
summarized in Fig. 5. As shown in Fig.
5A, exposure to M-PKI had no effect on the amplitude of wild-type Kv1.5
currents in oocytes preincubated in cytochalasin B (1 µM), a compound
that inhibits the addition of actin monomers to actin filaments
(0.95 ± 0.04 of control after 15 min, 0.87 ± 0.04 of
control after 10-min wash, n = 7). In contrast, Kv1.5
currents were reduced in control oocytes (0.80 ± 0.05 of control
after 15 min, 0.59 ± 0.11 of control after 10-min wash, p < 0.05, n = 5). The difference
between the cytochalasin B-treated oocytes and control oocytes was
significant (p < 0.01 by two-way ANOVA). Similar
results were obtained with oocytes preincubated in cytochalasin D
(1.0 ± 0.04 of control after 15 min, 0.97 ± 0.06 of control
after 10-min wash, n = 4, p < 0.01 by
two-way ANOVA, data not shown). In contrast, pretreatment of oocytes
with either phalloidin, a stabilizer of actin microfilaments (10 µM, data not shown) ,or colchicine (50 µM), an agent that disrupts microtubules, had no effect on the inhibition of wild-type Kv1.5 currents by M-PKI (0.83 ± 0.12 of control after 15 min, 0.67 ± 0.19 of control after 10-min wash, n = 5). Thus, the
normal turnover of actin filaments is necessary for the full effect of
the inhibition of PKA on Kv1.5 current, suggesting that the actin
cytoskeleton is an important component of PKA signaling to Kv1.5
channels.
|
Role of
-Actinin-2 in the Modulation of Kv1.5 Currents by
PKA.
Recently, Fedida and coworkers (Maruoka et al., 2000
; Cukovic
et al., 2001
) showed that
-actinin-2, an actin-binding protein, interacted with the NH2 terminus of the Kv1.5
subunit. We investigated whether
-actinin-2 influenced the
regulation of wild-type Kv1.5 currents by PKA, with results summarized
in Fig. 6. Two days before electrophysiological assay, X. laevis oocytes were injected
with either 50 ng of antisense or sense oligonucleotides against
-actinin-2 or molecular biology-grade water. The next day, oocytes
were injected with cRNA encoding wild-type Kv1.5. As shown in A,
-actinin-2 antisense significantly reduced the magnitude of Kv1.5
current compared with oocytes injected with either
-actinin-2 sense
oligonucleotide or water. Peak Kv1.5 current recorded at a potential of
+50 mV was 1.0 ± 0.2 µA for antisense-treated oocytes
(n = 24), compared with 2.0 ± 0.4 µA for
sense-treated oocytes (n = 21) and 2.2 ± 0.3 µA
for water-injected oocytes (n = 25). To determine
whether the reduction in Kv1.5 currents was specific for Kv1.5
channels, we examined the effect of
-actinin-2 oligonucleotides on
channels encoded by Kv2.2. The magnitude of Kv2.2 currents was
unaffected by
-actinin-2 antisense oligonucleotide. Kv2.2 current
was 6.9 ± 2.1 µA for antisense-treated oocytes
(n = 7), 5.2 ± 1.5 µA for sense-treated oocytes
(n = 5) and 4.3 ± 1.1 µA for water-injected oocytes (n = 7, data not shown). These data imply that
-actinin-2 antisense treatment specifically reduces Kv1.5 currents.
|
-actinin-2 antisense
oligonucleotide had Kv1.5 currents ranging from 0 to 1 µA at a potential of +50 mV. To characterize the electrophysiological properties of Kv1.5 currents in
-actinin antisense-treated oocytes and their response to PKA inhibition, we selected oocytes that expressed currents greater than 1 µA. The electrophysiological properties of Kv1.5 currents in these oocytes treated with
-actinin-2 antisense oligonucleotide did not differ from control
oocytes. That is, Kv1.5 currents in oocytes treated with
-actinin-2
antisense activated at potentials greater than
20 mV.
VAct and s values were
13.8 ± 0.2 mV and
6.9 ± 0.2 mV for
-actinin-2 antisense-treated oocytes
(n = 9), and
15.6 ± 0.2 mV and s = 7.1 ± 0.1 mV for
-actinin-2 sense-treated oocytes
(n = 8, data not shown). The
t0.5 values were 9.4 ± 1.9 ms for
-actinin-2 antisense-treated oocytes and 10.4 ± 2.1 ms for
-actinin-2 sense-treated oocytes.
Fig. 6B shows the response of wild-type Kv1.5 currents to M-PKI in
oocytes injected with either
-actinin-2 antisense or sense oligonucleotides. M-PKI reduced Kv1.5 currents in oocytes injected with
actinin-2 sense oligonucleotide (0.91 ± 0.02 of control after 15 min M-PKI, and 0.77 ± 0.04 of control after 10-min wash
(n = 6, p < 0.001). In contrast, M-PKI
had no effect on Kv1.5 currents in oocytes injected with
-actinin-2
antisense oligonucleotide (1.04 ± 0.04 of control after 15 min
M-PKI, 1.01 ± 0.06 of control after 10-min wash,
n = 6). Thus, the results with cytochalasins B and D,
and
-actinin-2 antisense suggest that the reduction in Kv1.5
currents observed after the inhibition of basal PKA activity requires
an intact actin cytoskeleton and
-actinin-2.
Phosphatase Modulation of Kv1.5 current.
The data above
suggest that Kv1.5 currents are fully activated by basal PKA activity
in X. laevis oocytes and that inhibition of PKA activity by
PKA inhibitor peptides reveals the action of endogenous phosphatases.
To investigate whether the suppression of wild-type Kv1.5 current by
PKA inhibitor peptides was consistent with the action of endogenous
phosphatases we examined the effect of exogenous alkaline phosphatase
on wild-type Kv1.5 current, with the data summarized in Fig.
7. Control Kv1.5 currents were recorded
for 10 min before oocytes were injected using a third microelectrode
with alkaline phosphatase (50 nl of 1 U/µl alkaline phosphatase to
give a final estimated intraoocyte concentration of 0.05 U), and the
currents monitored for a further 30 min. Control oocytes were injected
with boiled alkaline phosphatase (heated to 100°C for 3 h and
allowed to cool to room temperature before injection). Fig. 7A shows
that injection of alkaline phosphatase caused a slowly developing
inhibition of peak Kv1.5 current over 30 min after injection. Peak
Kv1.5 current was 0.97 ± 0.02 of control at 0 min after
injection, and decreased to 0.79 ± 0.03 of control after 15 min,
and 0.58 ± 0.06 of control 30 min after injection
(p < 0.001, n = 7). In contrast,
oocytes injected with boiled alkaline phosphatase did not show a
significant inhibition of peak Kv1.5 current (0.88 ± 0.09 of
control 30 min after injection, n = 6). The reduction
in Kv1.5 current in oocytes injected with alkaline phosphatase was
significantly different from oocytes injected with boiled alkaline
phosphatase (p < 0.01, two-way ANOVA). Injection of
alkaline phosphatase did not affect the
t0.5 of wild-type Kv1.5 current (4.8 ± 0.9 ms 0 min after injection versus 4 ± 0.7 ms 30 min
postinjection, n = 7). Alkaline phosphatase caused a hyperpolarizing shift in VAct from
20.1 ± 0.2 mV 0 min after injection to
25.4 ± 0.5 mV 30 min after
injection (n = 7) but with no change in the slope
(s = 7.3 ± 0.2 mV versus 6.3 ± 0.4 mV,
n = 7). Thus, injection of alkaline phosphatase
suppressed wild-type Kv1.5 current in a similar manner to that after
inhibition of PKA.
|
| |
Discussion |
|---|
|
|
|---|
We investigated the regulation by PKA of Kv1.5 currents expressed heterologously in X. laevis oocytes to develop information useful in understanding regulatory systems active in cardiac and vascular myocytes. This approach has an advantage in enabling the study of currents mediated by identified Kv channels. We found that treatments designed to increase levels of cAMP and PKA activity were without effect on Kv1.5 current amplitude, whereas either the inhibition of PKA by highly specific peptide inhibitors or the addition of exogenous alkaline phosphatase reduced Kv1.5 currents. Thus, the basal PKA activity in resting oocytes is maximally effective in increasing Kv1.5 currents.
We conclude that the amplitude of Kv1.5 current is increased by the
phosphorylation of a protein by PKA. An obvious candidate substrate for
PKA is the Kv1.5
subunit itself. Indeed, this is the mechanism by
which
-adrenergic activation of PKA increases Kv1.2 currents in
X. laevis oocytes (Huang et al., 1994
). With regard to
Kv1.5, analysis of the amino acid coding sequence of canine Kv1.5
subunit using DNASIS sequence analysis software (Hitachi Software
Engineering Co., Ltd., Yokohama, Japan) identified only two consensus
sequences for PKA phosphorylation (R/K-R/K-X-S/T), both of which are on
the COOH terminal at Ser538 and
Ser545. Furthermore, the Kv1.5
subunit is
phosphorylated by PKA in vitro (Williams et al., 1998
), although there
are no data supporting a regulatory function for this phosphorylation.
Indeed, our observation that the response of the Kv1.5
C59 mutant
channels (which lack both PKA phosphorylation sites) to inhibition of
PKA was identical to that of wild-type channels implies that
phosphorylation of these consensus sites is not necessary for
regulation of Kv1.5 currents by PKA.
The reduction of Kv1.5 currents by the inhibition of PKA by M-PKI was
attenuated in oocytes incubated in cytochalasins B and D, treatments
that inhibit actin polymerization in oocytes (Theodoropoulos et al.,
1994
), and was abolished when oocytes were injected 2 days before
recording with antisense cRNA designed to reduce synthesis of
-actinin-2. These data imply that the actin cytoskeleton plays an
essential role in the regulation of Kv1.5 currents by PKA. Two
mechanisms have been proposed to link Kv1 family channels to the
cytoskeleton: binding to PDZ proteins [all Kv1 channels, (Jing et al.,
1997
; Sheng and Pak, 2000
)] and binding to
-actinin-2 [Kv1.5 and
Kv1.4, (Maruoka et al., 2000
;Cukovic et al., 2001
)]. We considered the
PDZ-binding domain of Kv1.5 a likely source for an interaction of Kv1.5
channels with the cytoskeleton and PKA, and we investigated this by
deleting this domain in our Kv1.5
C59 mutant channel. However, the
reduction of the Kv1.5
C59 currents by inhibition of PKA was not
different from the effect seen in wild-type currents, implying that the
PDZ-binding domain is not required for the regulation of Kv1.5 currents
by PKA.
An alternative mechanism for linking Kv1.5 channels to the cytoskeleton
is by binding to
-actinin-2 as described by Fedida and coworkers
(Maruoka et al., 2000
; Cukovic et al., 2001
). These authors also showed
that this interaction was functionally important. In particular, Kv1.5
currents in stably transfected HEK293 cells were increased by more than
2-fold by exposure (2 to 24 h) to cytochalasin D or to antisense
cRNA designed to reduce
-actinin-2 synthesis. In contrast, we found
that a similar exposure to cytochalasins had no effect on the magnitude
of basal Kv1.5 currents and that treatment of oocytes with antisense
specifically targeted against
-actinin-2 reduced the amplitude of
Kv1.5 current in X. laevis oocytes. These observations imply
different regulatory mechanisms in the two expression systems. If
similar differences are found in native cells (cardiac myocytes, smooth
muscle myocytes, neurons) they could contribute to the varied responses
of native Kv currents to PKA (Li et al., 1996
; Ren et al., 1996
; Aiello
et al., 1998
; Evans et al., 1999
). In our study, exposure to
cytochalasins or
-actinin-2 antisense attenuated or abolished the
reduction in Kv1.5 current by inhibition of PKA, respectively. These
findings indicate that
-actinin-2 is a component of a signaling
system regulating the activity of Kv1.5 channels. This relationship
between Kv1.5 channels and
-actinin-2 is similar to that between
-actinin-2 and NMDA receptors expressed in HEK293 cells (Wyszynski
et al., 1997
).
We have considered two mechanisms to explain how an intact actin
cytoskeleton might contribute to the reduction of Kv1.5 currents by the
inhibition of PKA. First, actin and
-actinin-2 might localize PKA to
its substrate such that cytochalasin and the antisense treatment would
disrupt this localization and the phosphorylation of the substrate.
This idea is attractive because it provides a ready explanation for the
high basal activation of the Kv1.5 currents. This scheme predicts that
disruption of the cytoskeleton would lead PKA to drift away from the
vicinity of the channel, initiating dephosphorylation and reduction of
Kv1.5 currents. However, our data show that the magnitude of Kv1.5
currents remains unchanged after the disruption of the cytoskeleton.
Accordingly, although the cytoskeleton may target PKA to its substrate
in X. laevis oocytes, that targeting is not essential in
understanding our results. We have also considered the possibility that
actin and
-actinin-2 localize a protein phosphatase to a substrate important in the regulation of Kv1.5. We initially tested inhibitors of
the serine/threonine family of protein phosphatases but found no effect
on the reduction of Kv1.5 currents by M-PKI. In contrast, we showed
that preincubation of oocytes in sodium orthovanadate, a PTP inhibitor,
abolished the reduction of Kv1.5 currents by M-PKI, indicating that the
action of tyrosine phosphatase is necessary for the reduction of Kv1.5
current by inhibition of PKA in X. laevis oocytes. Recently,
Xu et al. (2001)
showed that PTP associated with F-actin in a variety
of cell lines, supporting the idea that the actin cytoskeleton may
localize a PTP in the vicinity of the Kv1.5 channel.
PTP mediated the reduction of Kv1.5 currents after inhibition of PKA
activity, suggesting that Kv1.5 currents were also modulated by a
tyrosine kinase. Indeed we found that the tyrosine kinase inhibitor
genistein reduced the magnitude of Kv1.5 currents in X. laevis oocytes, and that this reduction was abolished by sodium orthovanadate. We note that both sodium orthovanadate and genistein are
relatively nonselective inhibitors of PTP and tyrosine kinase, respectively. However, the ability of sodium orthovanadate to abolish
the inhibition of Kv1.5 currents by genistein indicates that sodium
orthovanadate indeed inhibits the activity of an endogenous PTP in
X. laevis oocytes. Recently, Cukovic et al. localized the
-actinin-2 binding region on human Kv1.5 to 76 amino acids between residues 73 and 148 (Cukovic et al., 2001
). This region encodes two
proline-rich SH3-binding domains and the T1'A' multimerization domain
(Scannevin and Trimmer, 1997
). Interestingly, the SH3-binding domain of
cloned human Kv1.5 (between residues 62 and 83) and native Kv1.5 in
human myocardium directly associates with Src tyrosine kinase, and
human Kv1.5 is tyrosine phosphorylated (Holmes et al., 1996
). However
the response of Kv1.5 currents to Src tyrosine kinase varies between
cell types; Kv1.5 current is suppressed when coexpressed with v-Src in
HEK293 cells (Holmes et al., 1996
) whereas Kv1.5 currents are increased
by Src in cultured spinal cord astrocytes (MacFarlane and Sontheimer,
2000
).
In summary, the results presented here reveal that Kv1.5 currents are
fully up-regulated by basal PKA and tyrosine kinase activity in
X. laevis oocytes. However, our data with the mutant Kv1.5
C59 channel indicate that regulation of Kv1.5 currents by PKA
does not require the two phosphorylation sites on the COOH terminus of
Kv1.5. If direct phosphorylation of the Kv1.5
subunit is important,
then the channel must be phosphorylated on one of the less favorable
serine or threonine residues that remain on the mutated Kv1.5
C59
channel (R-X-X-S/T or R-X-S/T), or on a tyrosine residue (X-E/D-Y-X).
Analysis of amino acid coding sequence of canine Kv1.5
subunit
identifies four potential candidates that remain on the Kv1.5
C59
channel: Tyr149, Ser157,
and Tyr228 on the NH2
terminus and Thr537 on the COOH terminus.
Deletion analysis of these four sites is required to assess the role of
these residues in the regulation of Kv1.5 by PKA. Inhibition of PKA
activity by specific PKA inhibitor peptides reveals that the reduction
in Kv1.5 currents is mediated by PTP. Furthermore, the modulation of
Kv1.5 by PTP requires an intact actin cytoskeleton and the
actin-binding protein
-actinin-2. Therefore the
Kv1.5/
-actinin-2/actin link and tyrosine kinase may be important in
mediating the increase in IKur currents in human
and rat atrial myocytes and smooth muscle after
-adrenergic receptor stimulation.
| |
Footnotes |
|---|
Received August 9, 2001; Accepted October 18, 2001
This work was performed during the tenure of a postdoctoral fellowship (AHA Western Affiliate 9920026Y; awarded to H.S.M.) and was also supported by National Institutes of Health grant DK41315.
Dr. J. L. Kenyon, Ph.D., Dept. of Physiology and Cell Biology MS-352, University of Nevada School of Medicine, Reno, NV 89557-0046. E-mail: kenyon{at}physio.unr.edu
| |
Abbreviations |
|---|
Kv, delayed rectifier potassium currents; PKA, cAMP-dependent protein kinase; ANOVA, analysis of variance; IBMX, 3-isobutyl-1-methylxanthine; PKI, protein kinase A inhibitor peptide; M-PKI, myristoylated PKA inhibitor peptide 14-22 amide; PDZ, PSD-95, Disc-large, and ZO-1; PTP, protein tyrosine phosphatase; HEK, human embryonic kidney.
| |
References |
|---|
|
|
|---|
-Adrenoceptor activation and PKA regulate delayed rectifier K+ channels of vascular smooth muscle cells.
Am J Physiol
275:
H448-H459.
channels in heart.
Circ Res
71:
1002-1007This article has been cited by other articles:
![]() |
H. Soh and S. A. N. Goldstein ISA Channel Complexes Include Four Subunits Each of DPP6 and Kv4.2 J. Biol. Chem., May 30, 2008; 283(22): 15072 - 15077. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. G. Langdon, S. C. Goetz, A. E. Berg, J. T. Swanik, and F. L. Conlon SHP-2 is required for the maintenance of cardiac progenitors Development, November 15, 2007; 134(22): 4119 - 4130. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Steele, J. Eldstrom, and D. Fedida Mechanisms of cardiac potassium channel trafficking J. Physiol., July 1, 2007; 582(1): 17 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lu, Q. Zhang, V. Timofeyev, Z. Zhang, J. N. Young, H.-S. Shin, A. A. Knowlton, and N. Chiamvimonvat Molecular Coupling of a Ca2+-Activated K+ Channel to L-Type Ca2+ Channels via {alpha}-Actinin2 Circ. Res., January 5, 2007; 100(1): 112 - 120. [Abstract] [Full Text] [PDF] |
||||